Preliminary evaluation of the commercial kit Chagas (Trypanosoma cruzi) IgG-ELISA® in Colombian individuals

Mónica Llano, Paula Pavía, Astrid Carolina Flórez, Adriana Cuéllar, John Mario González, Concepción Judith Puerta, .

Keywords: Chagas disease/diagnosis, Trypanosoma cruzi, antibodies, enzyme-linked immunosorbent assay, polymerase chain reaction

Abstract

Introduction: The diagnosis of Chagas’ disease is essential to provide early treatment and improve patients’ prognosis. The discriminatory efficiency of the serological tests varies according to the disease prevalence and the test-antigen used.

Objective: To evaluate the discriminatory efficiency of the commercial kit Chagas (Trypanosoma cruzi) IgG-ELISA® (Nova Tec Immunodiagnostica GmbBH) in a group of Colombian individuals, using indirect immunofluorescence antibody testing (IFAT) and enzyme immunoassay (ELISA) tests as references.

Materials and methods: Seventy-eight samples from chronic chagasic patients (36 asymptomatic and 42 symptomatic) and 21 healthy controls were included. Seventeen samples from non-infected people with Chagas’ disease epidemiological risk, seven with leishmaniasis and nine with non-chagasic cardiomyopathy were also analyzed. Real time PCR was performed on four individuals whose results differed among tests.

Results: Significant differences at 450 nm optical absorbance were found (p<0.0001) when the median absorbance values of healthy controls (0.143), asymptomatic (2.401) and symptomatic (2.776) chagasic patients were compared, as well as when asymptomatic and symptomatic patients (p=0.0408) and seronegative people with epidemiological risk (0.232), cardiomyopathy (0.367) or leishmaniasis (0.337) were compared with chagasic patients (p<0.0001). Finally, there were differences among healthy controls and non-infected people with epidemiological risk (p=0.0264), patients with non-chagasic cardiomyopathy (p=0.0015) and patients with leishmaniasis (p=0.002). Real-time PCR was positive in three out of four analyzed cases.

Conclusions: The commercial ELISA test allowed us to discriminate the chagasic patients from the controls. A phase II study of diagnostic tests for determining field reliability of this test is required.

Downloads

Download data is not yet available.
  • Mónica Llano Laboratorio de Parasitología Molecular, Departamento de Microbiología, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, D.C., Colombia
  • Paula Pavía Laboratorio de Parasitología Molecular, Departamento de Microbiología, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, D.C., Colombia
  • Astrid Carolina Flórez Grupo de Parasitología, Instituto Nacional de Salud, Bogotá, D.C., Colombia
  • Adriana Cuéllar Grupo de Inmunobiología y Biología Celular, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, D.C., Colombia
  • John Mario González Grupo de Ciencias Básicas Médicas, Facultad de Medicina, Universidad de los Andes, Bogotá, D.C., Colombia
  • Concepción Judith Puerta Laboratorio de Parasitología Molecular, Departamento de Microbiología, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá, D.C., Colombia
How to Cite
1.
Llano M, Pavía P, Flórez AC, Cuéllar A, González JM, Puerta CJ. Preliminary evaluation of the commercial kit Chagas (Trypanosoma cruzi) IgG-ELISA® in Colombian individuals. biomedica [Internet]. 2014 Jun. 1 [cited 2024 May 12];34(2):228-36. Available from: https://revistabiomedica.org/index.php/biomedica/article/view/1580

Some similar items:

Published
2014-06-01
Section
Original articles

Altmetric

Article metrics
Abstract views
Galley vies
PDF Views
HTML views
Other views
QR Code